Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Lenercept evaluated in phase II for sepsis/septic shock; development for RA halted

Oct. 15, 1997

New agent for restenosis reported by Taiho

Oct. 15, 1997

PRIME II: another heart failure drug associated with increased mortality

Oct. 15, 1997

Cardiovascular/Renal Drugs Advisory Committee meets this month

Oct. 14, 1997

DCLHb evaluated in critically ill patients

Oct. 13, 1997

CV Therapeutics moves ranolazine to phase III

Oct. 13, 1997

Renal effects of NO donor FK-409 in dogs

Oct. 10, 1997

BMS and ICAgen establish ion channel collaboration

Oct. 10, 1997

Hoechst discloses antiischemic agents

Oct. 10, 1997

Spotlight on angiotensin II blocker/ACE inhibitor combination therapy

Oct. 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...